Immunotherapy for the Treatment of Breast Cancer Guideline Overview – SITC CPG Webinar

When:  Oct 29, 2021 from 13:00 to 14:00 (ET)
On Friday, October 29, 2021 from 1 – 2 p.m. ET, join leading experts from the SITC Breast Cancer Immunotherapy Guideline Expert Panel for the "Immunotherapy for the Treatment of Breast Cancer Guideline Overview," a SITC Clinical Practice Guideline Webinar. This FREE CME-, CNE-, CPE-certified webinar will include selected recommendations from the recently-published Clinical Practice Guideline (CPG) that are applicable to the most common clinical scenarios for a disease setting/modality. A dedicated question-and-answer session during the webinar will provide an opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations.

Webinar Faculty:
  • Moderator: Rita Nanda, MD — University of Chicago (Expert Panel Member)
  • Elizabeth A. Mittendorf, MD, PhD — Dana-Farber/Brigham and Women's Cancer Center (Expert Panel Member)
  • David B. Page, MD — Earle A. Chiles Research Institute (Expert Panel Member)

Learning Objectives:

Upon completion of this program, participants will be able to:

  1. Select appropriate diagnostics and biomarker testing tailored to the clinical setting for a patient being considered for immunotherapy based on the expert panel recommendations in the SITC Clinical Practice Guideline (CPG)
  2. Implement immunotherapy treatments effectively and appropriately for breast cancer according to the recommendations in the CPG
  3. Appraise patterns of response to immunotherapy in order to appropriately monitor and manage patients during treatment


*You will be given the option to register for one or multiple webinars in this series. Please note which ones are approved for credit.

Continuing Education Credits will be available for physicians, nurses, and pharmacists who attend the live webinar. Click here to view full accreditation information.

This webinar is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.